Physician profile
Radha Ram
NPI 1093081085
$1,590.36
in general payments reported to CMS, 2019-2025
14 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $211 · 2022: $106 · 2023: $254 · 2024: $237 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $293.11 | 2019-2024 | Tecnis Simplicity |
| Abbvie INC. | $216.41 | 2019-2022 | |
| Biotissue Holdings INC. | $204.87 | 2019-2020 | |
| Rxsight INC | $127.22 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Genentech USA, INC. | $126.78 | 2023 | Vabysmo |
| Alcon Vision LLC | $119.88 | 2024 | Clareon |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Aerie Pharmaceuticals, INC. | $117.87 | 2019 | |
| Bausch & Lomb Americas INC. | $107.91 | 2025 | Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $94.70 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $16.00 | 2025 | Caldolor |
| Travere Therapeutics, INC. | $9.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Ram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.